Retatrutide reduced weight, but safety questions remain
Hunger may fade before your weight starts to fall. Phase 2 checks whether a drug helps and what trouble it causes. Phase 3 means larger tests before possible approval.
Early weight loss came with unanswered health questions
Thinking about food soon after a meal can be tiring. Eli Lilly made retatrutide for studies of weight loss and type 2 diabetes. With that illness, insulin, the hormone that helps sugar enter your cells for fuel, doesn't work well enough. Retatrutide had no approval for a doctor's prescription anywhere as of 2026.
Retatrutide copies three hormones, chemicals your body sends between organs. GLP-1 helps curb hunger and release insulin when sugar is high. GIP increases insulin after a meal and affects the use of fuel in fat cells. Most medicines like these copy GLP-1 alone or pair that hormone with GIP, whereas retatrutide also copies glucagon to help the liver draw energy from stored fat.
This Phase 2 study was a 48-week test in around 338 adults, leaving doubts about lasting effects and people whose health differs from theirs. Even so, the group receiving the most drug had an average loss of 24.2% of their weight. With placebo, an injection containing no medicine, people lost 2.1% [1]. Your weight won't necessarily follow either group's average.
I hadn't expected such a large loss in that early study. Larger Phase 3 tests must still check harm to hearts and kidneys. Losing weight doesn't settle every question about your health. The effects page covers study risks and unproved claims from people trying research products.
What does retatrutide do when sugar stays too high
Your sugar test may improve without answering every question about your health. Retatrutide copies GLP-1, a hormone that helps produce insulin when blood sugar has risen. Insulin is a hormone your body uses to get sugar into cells for energy. The blood still held roughly half of the retatrutide after 6 days, allowing weekly study shots under the skin with doctors watching for harm [4].
Lab tests examined how the drug works, rather than anyone's weight loss [3]. Retatrutide copied GIP most strongly; that hormone increases insulin release after meals and affects fat cells. That extra help may add weight loss beyond the benefit of less hunger. Retatrutide's weaker glucagon effect may burn fat without the large sugar rise caused by glucagon acting at full strength.
The Phase 2 study, an early check on how well the drug works and what harm it causes, followed 281 adults with type 2 diabetes in a 36-week test, with doctors checking their health along the way. Such a small test can't settle how someone of your age would respond. At 12 mg, a blood test showed less sugar over a 3-month span. Placebo shots, containing no study drug, barely changed that test.
People receiving the drug lost 16.94% of their starting weight [2]. Those receiving placebo lost 3.00% of their starting weight. Sugar and weight fell more in groups receiving higher amounts. Doctors supervised those amounts; the findings don't tell you how much would be safe.
How does retatrutide work when you eat less
Retatrutide may affect your weight through more than reduced hunger. By copying a hunger hormone, retatrutide delays the passage of food from your stomach. Retatrutide also helps release insulin when sugar in blood is high. Insulin moves that sugar into cells that need fuel.
Releasing insulin mainly when sugar is high makes a dangerous sugar drop less likely than with some older diabetes drugs; those drugs can work even when your sugar isn't high. Your sugar could still fall dangerously low with retatrutide, especially alongside other diabetes treatment. That risk needs care from someone who knows your medicines.
GIP, another hormone retatrutide copies, adds insulin after meals and affects fat cells. Glucagon helps the liver burn stored fat, releasing energy and heat. That use of fat doesn't depend entirely on eating less. Curbing hunger and using stored fat together may explain the early weight loss.
A review gathers earlier findings rather than testing another group of people. The 2025 review judged the Phase 1/2 weight loss a major advance [6]. Its authors thought the loss exceeded that found with earlier medicines. The review couldn't establish how long your benefit would last.
A separate 2026 report examined tests related to burning fat for fuel. Higher amounts went with less fat in blood and better use of insulin. In people without type 2 diabetes, the authors' calculations suggested that increased fat burning explained some weight loss [12]. You can't read your own likely weight loss from that estimate of fat burning.
Fat can also build up inside the liver and cause trouble. The Retatrutide research page covers the studies that measured that fat. Liver tests improved, but lasting health benefits remain uncertain. Longer studies must check your heart and kidney risks too.
Retatrutide has no approved medicine for a prescription
A falling weight doesn't mean a drug has passed all its checks. No drug agency had given retatrutide prescription approval as of 2026. There isn't an approved retatrutide medicine for your doctor to prescribe. Phase 3, the larger studies before possible approval, must still test benefits and harm.
TRIUMPH-2 follows adults whose high weight comes with type 2 diabetes [7]. Another study checks serious heart troubles and kidney health [8]. A further test compares retatrutide against tirzepatide in the same study [9]. The first Phase 1 test, an early check in people, ended in 2022 [10].
A bottle marked for research hasn't passed the checks required for medicine. Its label can't establish that the contents match what the label says. The bottle could contain a different substance or an incorrect amount. No research label can give you the assurance of an approved medicine.
Poor handling can let germs into a shot, and someone outside a study won't have its doctors checking their health or watching for harm. The published retatrutide results came from supervised Phase 2 tests. Those early tests included medical checks as well as study medicine. The findings don't establish the safety of an unknown bottle for you.
Tirzepatide has completed approval checks that retatrutide still hasn't passed. That difference affects which medicine a doctor can prescribe for your care. The retatrutide vs tirzepatide page describes the findings for each drug. Their Phase 3 comparison remains unfinished, so claims that one works better need more evidence.
Retatrutide availability needs the larger Phase 3 tests
Your chance of a prescription depends on more than promising weight loss. Phase 3 means the larger tests before a drug can seek approval. Several Phase 3 studies were still accepting people as of mid-2026. Eli Lilly hadn't set a promised approval date for retatrutide.
Even successful Phase 3 studies would still require an FDA review. Approval isn't automatic when a study ends. A wait of 1-3 years after testing, with approval no earlier than 2027-2028, is only a guess. Until approval, medical care with the drug depends on joining an active study.
The 2025 review assessed existing reports rather than treating new patients [11]. Its authors judged medicines copying all three hormones strongest for weight loss. Better blood tests led the authors to expect benefits for heart health and sugar control. Phase 3 must still check whether those hopes mean less serious illness for you years later.